Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Axsome Therapeutics, Inc. | axsm-20191231ex322d3cf29.htm |
| EX-32.1 - EX-32.1 - Axsome Therapeutics, Inc. | axsm-20191231ex321894c95.htm |
| EX-31.2 - EX-31.2 - Axsome Therapeutics, Inc. | axsm-20191231ex312ca5bff.htm |
| EX-31.1 - EX-31.1 - Axsome Therapeutics, Inc. | axsm-20191231ex311b2ca87.htm |
| EX-10.17 - EX-10.17 - Axsome Therapeutics, Inc. | axsm-20191231ex101740c34.htm |
| EX-10.15 - EX-10.15 - Axsome Therapeutics, Inc. | axsm-20191231ex1015f938b.htm |
| EX-4.13 - EX-4.13 - Axsome Therapeutics, Inc. | axsm-20191231ex4132a1d5e.htm |
| 10-K - 10-K - Axsome Therapeutics, Inc. | axsm-20191231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements:
|
· |
Registration Statement (Form S-8 No. 333-217002) pertaining to the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan; |
|
· |
Registration Statement (Form S-8 No. 333-208579) pertaining to the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan; |
|
· |
Registration Statement (Form S-8 No. 333-230296) pertaining to the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan; |
|
· |
Registration Statement (Form S-8 No. 333-226824) pertaining to Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan; and |
|
· |
Registration Statement (Form S-3ASR No. 333-235372) of Axsome Therapeutics, Inc. and in the related Prospectus; |
of our report dated March 12, 2020, with respect to the consolidated financial statements of Axsome Therapeutics, Inc. included in this Annual Report (Form 10-K) of Axsome Therapeutics, Inc. for the year ended December 31, 2019.
|
|
/s/ Ernst & Young LLP |
|
|
|
|
New York, NY |
|
|
March 12, 2020 |
|